Glioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis

• Christine E. Brown ,

  Contributed equally to this work with: Christine E. Brown, Charles D. Warden

  * E-mail: cbrown@coh.org

  Affiliation Department of Cancer Immunotherapy & Tumor Immunology and Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute and City of Hope National Medical Center, Duarte, California, United States of America

  ⨯
• Charles D. Warden ,

  Contributed equally to this work with: Christine E. Brown, Charles D. Warden

  Affiliation Department of Molecular Medicine, Beckman Research Institute and City of Hope National Medical Center, Duarte, California, United States of America

  ⨯
• Renate Starr,

  Affiliation Department of Cancer Immunotherapy & Tumor Immunology and Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute and City of Hope National Medical Center, Duarte, California, United States of America

  ⨯
• Xutao Deng,

  Affiliation Department of Molecular Medicine, Beckman Research Institute and City of Hope National Medical Center, Duarte, California, United States of America

  ⨯
• Behnam Badie,

  Affiliation Department of Neurosurgery, Beckman Research Institute and City of Hope National Medical Center, Duarte, California, United States of America

  ⨯
• Yate-Ching Yuan,

  Affiliation Department of Molecular Medicine, Beckman Research Institute and City of Hope National Medical Center, Duarte, California, United States of America

  ⨯
• Stephen J. Forman ,

  ¶Co-senior authors.

  Affiliation Department of Cancer Immunotherapy & Tumor Immunology and Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute and City of Hope National Medical Center, Duarte, California, United States of America

  ⨯
• Michael E. Barish

  ¶Co-senior authors.

  Affiliation Department of Neurosciences, Beckman Research Institute and City of Hope National Medical Center, Duarte, California, United States of America

  ⨯